The 340B Drug Discount Program has faced turmoil in recent years. 340B covered entities are ﬁghting to protect this essential program from the drug industry, the administration, and critics in Congress. This program also faces challenging shifts in market dynamics. Yet, there is hope. Dave Borden, PSG’s CEO, shared his outlook for the 340B program and what covered entities can do to keep 340B strong.
Want to dive deeper into what is happening on Capitol Hill?
Join PSG on May 22 for an interactive webinar session as we discuss key 340B state trends.